<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the diagnosis of hypersensitivity pneumonitis (HP)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the diagnosis of hypersensitivity pneumonitis (HP)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Approach to the diagnosis of hypersensitivity pneumonitis (HP)</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="50%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="2"><strong>Characteristics that help in the diagnosis of HP in patients with respiratory +/– constitutional symptoms (eg, cough, breathlessness, fever, fatigue) and absence of features to suggest systemic rheumatic disease</strong></td> </tr> <tr class="divider_bottom"> <td colspan="2"> <ol class="numbers_to_nine"> <li>Known exposure to offending antigen identified by: <ol class="numbers_to_nine" style="list-style-type: upper-alpha;"> <li>History of appropriate exposure: Aerobiologic or microbiologic investigations of the environment that confirm the presence of an inciting antigen </li> <li>The presence of specific IgG antibodies in serum against the identified antigen (serum precipitins, ELISA, or ImmunoCAP)* </li> </ol> </li> </ol> </td> </tr> <tr class="divider_bottom"> <td colspan="2"> <ol class="numbers_to_nine" start="2"> <li>Compatible HRCT findings: <ol class="numbers_to_nine" style="list-style-type: upper-alpha;"> <li>Acute/subacute: Upper and middle lobe predominant small centrilobular nodules, ground-glass attenuation, and lobular areas of decreased attenuation and vascularity </li> <li>Chronic/fibrotic: Upper and middle lobe predominant fibrosis, peribronchovascular fibrosis, honeycombing, mosaic attenuation, air trapping, centrilobular nodules, and relative sparing of bases </li> </ol> </li> </ol> </td> </tr> <tr class="divider_bottom"> <td colspan="2"> <ol class="numbers_to_nine" start="3"> <li>BAL lymphocytosis: Supports diagnosis of HP if lymphocytosis, but nonspecific and not always needed <ol class="numbers_to_nine" style="list-style-type: upper-alpha;"> <li>Lymphocytosis &gt;20%, often &gt;50% </li> <li>Mycobacterial stains and culture negative </li> </ol> </li> </ol> </td> </tr> <tr class="divider_bottom"> <td colspan="2"> <ol class="numbers_to_nine" start="4"> <li>Positive inhalation challenge testing by: <ol class="numbers_to_nine" style="list-style-type: upper-alpha;"> <li>Reexposure to the environment </li> <li>Inhalation challenge to the suspected antigen in a hospital setting (not widely available or standardized) </li> </ol> </li> </ol> <ol class="numbers_to_nine" style="list-style-type: none;"> <li>Only performed in selected patients </li> </ol> </td> </tr> <tr class="divider_top"> <td colspan="2"><strong>Confident HP without biopsy:</strong></td> </tr> <tr class="divider_bottom"> <td colspan="2"> <ul class="decimal_heading"> <li>Criteria 1, 2, and 3 are met – Histopathologic confirmation of the diagnosis is not needed in the majority of such cases </li> <li>Criteria 1 and 2 are met – BAL not needed for patients with clear exposure, typical HRCT, and response to antigen avoidance </li> </ul> </td> </tr> <tr> <td colspan="2"><strong>Probable HP:</strong></td> </tr> <tr class="divider_bottom"> <td> <ul class="decimal_heading"> <li>Criteria 1 (A or B) and 3 are met, but HRCT more consistent with UIP, NSIP, CPFE, or OP. </li> <li>Criteria 2 and 3 are met, but no identifiable historical or serologic evidence of exposure. </li> </ul> </td> <td>Lung biopsy<sup>¶</sup> needed to confirm HP or identify alternate diagnosis.</td> </tr> <tr> <td colspan="2"><strong>Possible HP</strong></td> </tr> <tr class="divider_bottom"> <td> <ul class="decimal_heading"> <li>Criteria 1 (A or B) is met. HRCT more consistent with other IIP; BAL not done or without lymphocytosis. </li> <li>Criteria 1 (A or B) and 2 are met, but BAL does not show lymphocytosis. </li> </ul> </td> <td>Lung biopsy<sup>¶</sup> needed to confirm HP or identify alternate diagnosis.</td> </tr> <tr> <td colspan="2"><strong>HP unlikely but clinical features atypical for IPF</strong></td> </tr> <tr class="divider_bottom"> <td> <ul class="decimal_heading"> <li>Criteria 1, 2, 3 not met; HRCT more consistent with UIP, NSIP, CPFE, or OP. </li> </ul> </td> <td>Lung biopsy<sup>Δ</sup> may be appropriate to confirm HP or identify alternate diagnosis.</td> </tr> <tr class="divider_top"> <td colspan="2"> <p><strong>Interpreting results of lung biopsy</strong></p> Histopathologic features of HP include: <ol style="list-style-type: upper-alpha;"> <li>Poorly formed, noncaseating granulomas, multinucleated giant cells near respiratory or terminal bronchioles </li> <li>Chronic cellular bronchiolitis </li> <li>Chronic cellular pneumonitis with patchy lymphoplasmacytic infiltration </li> </ol> <p><strong>Presence of triad</strong>: Confident diagnosis of HP for probable or possible HP, need to exclude histopathological mimics, such as connective tissue disease-associated interstitial lung disease.</p> <p><strong>Presence of one or two features of triad</strong>: Likely HP in patients with clinical impression of "probable" HP or "possible" HP.</p> <p><strong>Predominant features of UIP, with subtle features of HP</strong> (eg, few granulomas or multinucleated giant cell): Could be fibrotic HP or IPF. Multidisciplinary conference may help clarify diagnosis.</p> <strong>Predominant features of a different interstitial lung disease (OP, NSIP, CPFE), but subtle features of HP</strong> (eg, few granulomas or multinucleated giant cell): Unlikely to be HP unless criteria 1 or 2 is positive. Multidisciplinary conference may help clarify diagnosis.</td> </tr> </tbody></table></div><div class="graphic_footnotes">IgG: immunoglobulin G;

	ELISA: enzyme-linked immunosorbent assay; 

	HRCT: high resolution computed tomography; 

	BAL: bronchoalveolar lavage; 

	UIP: usual interstitial pneumonia; 

	NSIP: nonspecific interstitial pneumonia; 

	CPFE: combined pulmonary fibrosis emphysema; 

	OP: organizing pneumonia; 

	IIP: idiopathic interstitial pneumonia; 

	IPF: idiopathic pulmonary fibrosis; 

	TBLB: transbronchial lung biopsy; 

	TBCB: transbronchial cryobiopsy.<br/>	

	* A positive precipitin test even in the presence of a clear history of exposure to the identified antigen is merely suggestive of, rather than diagnostic of, a potential etiology.<br/>	

	¶ Lung tissue can be obtained by TBLB, TBCB, or video-assisted surgical biopsy. A multidisciplinary conference can help guide decision-making about whether to obtain TBLB prior to surgical lung biopsy, proceed directly to surgical biopsy, or avoid invasive procedures due to patient frailty or unlikely benefit.<br/>	

	Δ For patients in whom HP unlikely, surgical lung biopsy favored over TBLB or TBCB.</div><div class="graphic_reference">Reference: Vasakova M, Morell F, Walsh S, et al. Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. Am J Respir Crit Care Med 2017; 196:680.</div><div id="graphicVersion">Graphic 119874 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
